Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-02-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancermetastaticchemotherapypatientadjuvant
  Phrases that lowered it: and safetyefficacy andsafety ofeffect ofthe effect
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 28.3% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 320 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 191 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 75 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 1 (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Blinding: none (raises risk) · Design
• Drug's FAERS reports before start: 61239 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer NCT01069796 · started 2010 · scored riskier than 92% of active trials terminated
• Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer NCT00691379 · started 2008 · scored riskier than 86% of active trials completed
• A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer NCT01201265 · started 2011 · scored riskier than 56% of active trials completed
• Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer NCT01208480 · started 2010 · scored riskier than 65% of active trials completed
• A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel NCT01722968 · started 2012 · scored riskier than 89% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.